The privately held medical technology company is dedicated to the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's proprietary Hi-VNI technology products are used to treat patients of all ages suffering from respiratory distress, and it generates revenue primarily from sales of its Precision Flow systems to hospitals. Vapotherm is the inventor of high flow nasal cannula and its advanced form, Vapotherm high velocity therapy, which offers clinicians a reliable tool for multiple patient populations. The company is publicly traded on the NYSE under the ticker symbol "VAPO."